Sanaria featured in National Geographic magazine
Read the full story: Bedlam in the Blood, Malaria (Membership required). NatGeo Article|
Sanaria featured in ‘Kill or Cure’ documentary
Kill or Cure? The Malaria Vaccine takes viewers into the starkly different worlds of two cutting-edge investigators who may be moving us tantalizingly close to an achievement unheard of in the history of immunizations - an effective vaccine against a parasitic disease.
Sanaria Inc. Receives Multi-Year $3.47 Million U.S. NIH Phase I and Phase II Small Business Innovation Research Grants to Enhance Development of its Malaria Vaccine
Sanaria Inc., a Rockville, Maryland privately held company, announced the receipt of two multi-year Small Business Innovation Research (SBIR) Grants from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health. The grants will enhance the development of its whole parasite Malaria Vaccine. The Phase II grant is to establish multiple strains of the parasite that can be used to assess the effectiveness of Sanaria's Malaria Vaccine.
Bush recognizes social entrepreneurship
Like many such events, the recent White House Summit on malaria, which featured a speech and new grant announcements by Melinda Gates, was carefully choreographed with few surprises. But there was one.
President Bush began the closing keynote address by saying, “I want to thank those members of my Cabinet who are here, the ambassadors, the members of Congress, and I want to thank the social entrepreneurs who are with us today.” Bush then cited the Bill & Melinda Gates Foundation as “a fantastic example of social entrepreneurship, using business acumen to address social problems.”
Read more in the original |
$29.3M Gates grant boosts Sanaria
With the grant by the Bill and Melinda Gates Foundation announced Thursday, plus a new partnership with the Malaria Vaccine Initiative, Sanaria has reached $45 million in funding for developing a malaria vaccine.
Mosquito ‘factories’ to fight malaria
It's going to be fiddly work, but the saliva glands of mosquitoes are to be used as mini factories for churning out a novel vaccine against malaria. The vaccine is based on the whole parasite, rather than individual proteins, and may therefore work better than other vaccines in development because the body can mount a multi-pronged attack against it.
PATH Malaria Vaccine Initiative Announces New Partnership To Accelerate Development of Novel Malaria Vaccine Candidate MVI and Sanaria Inc. to Conduct Initial Safety and Test-of-Concept Trial
In a move that promises to expand the types of malaria vaccine candidates in clinical development, the PATH Malaria Vaccine Initiative (MVI) today announced a new partnership with Sanaria Inc., a Maryland company, to accelerate development of a unique malaria vaccine candidate.
A conversation with Stephen Hoffman
Scientist survives several near misses — including a crash-landing — before turning his efforts toward fighting malaria
Off on his own in South America, he gets typhoid. In California, he is infected with malaria. On his way to a research site in Africa, the plane carrying him crash-lands.
Is Stephen Hoffman, the leader of malaria-vaccine developer Sanaria, scared by his past skirmishes with death? Sometimes.
Read the full story in the latest Washington Business Journal.|
Sanaria CEO Hoffman Most Cited Author in the World
Essential Scientific Indicators has reported that Dr. Stephen L. Hoffman, Founder and Chief Executive Officer of Sanaria Inc., is the most cited author in the world for scientific papers on malaria published between 1995 and 2005.
Rockville’s Sanaria to test malaria vaccine
While Sanaria Inc. works to keep its focus on developing revenue streams, the estimated 3,000 children who die each day in a global resurgence of malaria add a humanitarian perspective for the Rockville company. This week, Sanaria, headed by CEO Stephen Hoffman, begins manufacturing its first run of a unique and promising malaria vaccine.
The Malaria Fighter
Sanaria's Dr. Hoffman is featured in Business 2.0 magazine's The Smart List edition.
An Interview with Dr. Stephen Hoffman
In Essential Science Indicators, Dr. Hoffman’s work can be found in the fields of Immunology and Microbiology. Dr. Hoffman is the founder, CEO, and Chief Scientific Officer of Sanaria, Inc. in Rockville, Maryland. In the interview below, he talks with Special Topics correspondent Gary Taubes about his highly cited work in malaria research.
Sanaria Inc. Receives Multi-Year $3 Million U.S. NIH Phase II Small Business Innovation Research Grant for Further Development of its Malaria Vaccine
Sanaria Inc., a Rockville, Maryland privately held company focused on development of an attenuated whole parasite Malaria Vaccine, announced the receipt of a multi-year Phase II Small Business Innovation Research Grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.
Sanaria Inc. Receives U.S. Army Award for Development of its Malaria Vaccine
Sanaria Inc., a Rockville, Maryland privately held company focused on development of an attenuated whole parasite Malaria Vaccine announced the receipt of a $4.09 million research and development award from the United States Army Medical Research Acquisition Activity Group in Fort Detrick, Maryland.
Sanaria gets $4M in gov’t funds for malaria vaccine
Sanaria has snagged a research grant worth more than $4 million from the Army to work on a malaria vaccine, which the biotech company hopes to have in human testing a year from now.
Hoffman Elected to Membership in the Institute of Medicine of National Academies
tephen L. Hoffman, M.D., Founder, Chief Executive and Scientific Officer of Sanaria Inc., Rockville, Maryland has been elected to membership in the Institute of Medicine (IOM) of the National Academies of Sciences.
Institute For Oneworld Health Receives Gates Foundation Grant To Fund Development Of Malaria Vaccine
The Institute for OneWorld Health, the first nonprofit pharmaceutical company in the U.S., announced today it has received a $1.4 million grant from the Bill & Melinda Gates Foundation to support development of a vaccine for the prevention and treatment of malaria, including for infants and children in the developing world.
Mosquito production mooted as fast track to malaria vaccine
In the October 2 issue of Nature, the News features a story about Sanaria's "audacious approach" to developing novel malaria vaccines.
Rationale and plans for developing a non-replicating, metabolically active, radiation-attenuated Plasmodium falciparum sporozoite vaccine
Summary
Annually, malaria causes >300 million clinical cases and 1·million deaths, is responsible for the loss of >1% of gross domestic product (GDP) in Africa and is a serious concern for travelers. An effective vaccine could have a dramatic impact on the disease. For 20 years, scientists have tried to develop modern, recombinant ‘subunit’ malaria vaccines. This has been difficult. In fact, there is only one recombinant protein vaccine on the market for any disease, and no vaccines based on synthetic peptides, recombinant viruses, recombinant bacteria or DNA plasmids. Most vaccines are based on attenuated or inactivated whole pathogens or |
Protection of Humans against Malaria by Immunization with Radiation-Attenuated Plasmodium falciparum Sporozoites
During 1989-1999, 11 volunteers were immunized by the bites of 1001-2927 irradiated mosquitoes harboring infectious sporozoites of Plasmodium falciparum (Pf) strain NF54 or clone 3D7/NF54. Ten volunteers were first challenged by the bites of Pf-infected mosquitoes 2-9 weeks after the last immunization, and all were protected. A volunteer challenged 10 weeks after the last immunization was not protected. Five previously protected volunteers were rechallenged 23-42 weeks after a secondary immunization, and 4 were protected.
